This is a type of cancer that starts in the blood cells, mainly in children and teenagers. It's called 'precursor' because it's a very early stage of cancer, like a seed before a plant grows. It often affects lymph nodes, skin, and bones.
Every report comes from a Lived member, sent anonymously.
Have you tried Vincristine for B-Cell Acute Lymphoblastic Leukemia?
B-cell acute lymphoblastic leukemia (B-ALL) is a fast-growing cancer of the bone marrow, the soft tissue inside bones where blood cells are made. It starts in lymphoblasts, the immature cells that would normally develop into B lymphocytes (B cells), the white blood cells that make antibodies. Instead of maturing, these cells multiply out of control and crowd out the healthy marrow. With too few normal red blood cells, white blood cells and platelets, people can develop tiredness and pale skin, frequent or lingering infections, fevers, and easy bruising or bleeding. Bone pain, swollen lymph nodes and a sense of fullness under the ribs from an enlarged spleen or liver are also common. "Acute" means the disease usually worsens within weeks if it is not treated, which is why treatment typically begins soon after diagnosis. B-ALL is the most common form of acute lymphoblastic leukemia (ALL), and ALL is the most common cancer in children. It also occurs in adults, who make up a little less than half of all cases. The same disease is sometimes called B-lymphoblastic lymphoma. When at least 20% of the cells in the bone marrow are lymphoblasts, it is called leukemia; when the disease is mainly in lymph nodes or other tissues with fewer blasts in the marrow, it is called lymphoma. Doctors regard these as two presentations of one cancer, which explains the longer catalog name.
B-ALL begins when blood-forming cells in the marrow acquire changes in their DNA that let them keep dividing without maturing. In most people, nobody can say why those changes happened. It is not caused by diet, exercise or anything a parent or patient did, and it is not contagious. A few factors are linked to a higher chance of developing ALL. These include certain inherited conditions, most notably Down syndrome; earlier treatment with chemotherapy or radiation therapy; and exposure to high levels of radiation. ALL is slightly more common in males and in White people. Risk is highest in children under 5, falls through young adulthood, and rises again after about age 50. Most people with these factors never develop ALL, and many people who do have none of them.
The first clue is often a complete blood count (CBC), a routine blood test that counts red cells, white cells and platelets. In B-ALL, red cells and platelets are usually low, and the white count can be low, normal or very high. A blood smear, in which the cells are examined under a microscope, may show lymphoblasts that should not be circulating in the blood. The diagnosis is confirmed with a bone marrow aspiration and biopsy. A hollow needle, usually placed in the hip bone after the area is numbed, removes a small sample of liquid marrow and bone. Specialists then run several tests on it. Immunophenotyping (also called flow cytometry) reads the markers on the surface of the cells to show that the leukemia comes from B cells rather than T cells. Chromosome and gene tests look for specific changes that strongly shape treatment. The most important is the Philadelphia chromosome, a swap between chromosomes 9 and 22 that creates an abnormal gene called BCR::ABL1. It is uncommon in young children and becomes more common with age. A lumbar puncture (spinal tap) checks the fluid around the brain and spinal cord for leukemia cells, because ALL can spread there. Imaging may look for enlarged lymph nodes or masses, especially when the lymphoma form is suspected. ALL does not have stages like many solid tumors. Instead, doctors assign a risk group. For children, standard risk generally means age 1 to under 10 with a white count below 50,000 per microliter at diagnosis; age 10 or older, a count of 50,000 or more, certain genetic changes and a slow response to the first month of treatment move a child into a higher-risk group. In adults, age, overall health, the white count and genetic findings play a similar role.
Treatment aims to bring about remission, meaning leukemia can no longer be found in the marrow and normal blood counts return, and then to eliminate the remaining cells that could cause a relapse. The main treatment is a combination of chemotherapy drugs given in planned phases. Induction, roughly the first month, is the most intense period and usually includes hospital stays. Consolidation, lasting several months, deepens the remission. Maintenance uses lower doses, largely pills taken at home such as daily 6-mercaptopurine and weekly methotrexate, and continues for most of the treatment period. Altogether, treatment usually lasts about 2 to 3 years in children and about 2 years in adults. Because ordinary chemotherapy does not reach the brain and spinal cord well, medicine is also injected into the spinal fluid at intervals throughout treatment to prevent or treat leukemia there. The genetic findings help choose added treatments. People with Philadelphia chromosome-positive B-ALL take a tyrosine kinase inhibitor, a targeted pill that blocks the abnormal BCR::ABL1 protein, such as imatinib (Gleevec) or dasatinib, alongside chemotherapy. Immunotherapies directed at markers on B cells are increasingly part of care. Blinatumomab (Blincyto) is an infusion that links a person's own T cells to leukemia cells so the T cells can destroy them; it is used during consolidation for some people and when leukemia remains detectable or returns. Inotuzumab ozogamicin is an antibody that carries a chemotherapy drug directly to B-ALL cells. CAR T-cell therapy (chimeric antigen receptor T-cell therapy) reprograms a person's own T cells in a laboratory to attack the leukemia and is used for certain relapsed or hard-to-treat cases. A stem cell transplant from a donor may be recommended for people at high risk of relapse, those whose leukemia does not fully respond, or those who relapse. It can improve the chance of lasting control but carries substantial risks of its own, which is why it is not used for everyone. Older adults, typically over 65, and people with other serious health problems may not tolerate the most intensive regimens and may receive reduced doses or gentler combinations. Throughout treatment, supportive care such as antibiotics and red cell and platelet transfusions matters as much as the cancer drugs themselves. Clinical trials testing new treatments are an option for many people.
Outcomes differ a great deal by age. About 90% of children with ALL are alive five years after diagnosis, and a child who is free of leukemia at five years is likely cured. Results in adults are less favorable: most reach remission, but about half of those later relapse, and outlook generally declines with age. In both groups, how quickly the leukemia responds to the first month of treatment and the genetic changes in the leukemia cells are among the strongest predictors. Very sensitive tests for measurable residual disease (MRD), meaning tiny amounts of leukemia left after treatment, are repeated during care and help decide whether treatment should be intensified. The first months are the hardest. Low blood counts make infections, fatigue and bleeding more likely, and frequent clinic visits, blood tests, bone marrow checks and lumbar punctures become routine. Daily life usually becomes more manageable during maintenance, when treatment is mostly oral, can often be taken at home and visits are less frequent. Taking maintenance medicines exactly as prescribed is important because missed doses raise the chance the leukemia comes back. After treatment ends, follow-up visits continue for years to watch for relapse and for late effects. Depending on the treatment received, these can include effects on the heart, bones, fertility, growth, learning and memory, and a small risk of a second cancer. Long-term survivorship clinics help track these.
See a doctor if you or your child have ongoing tiredness, pale skin, unexplained bruising or tiny red or purple spots on the skin (petechiae), bone pain, repeated infections or fevers, or painless swollen lymph nodes. These symptoms usually have other causes, but a simple blood count can check for leukemia. During treatment, call the cancer care team right away, at any hour, for a temperature above 100.4 F (38 C) or for shaking chills, because infection can become serious quickly when white blood counts are low. Go to an emergency department or call 911 for trouble breathing at rest, chest pain, or new confusion or unusual drowsiness during treatment, as these can be signs of a severe infection.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share what living with B-Cell Acute Lymphoblastic Leukemia is like, what's helped you, or ask the community a question.